JP2015516459A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015516459A5 JP2015516459A5 JP2015512121A JP2015512121A JP2015516459A5 JP 2015516459 A5 JP2015516459 A5 JP 2015516459A5 JP 2015512121 A JP2015512121 A JP 2015512121A JP 2015512121 A JP2015512121 A JP 2015512121A JP 2015516459 A5 JP2015516459 A5 JP 2015516459A5
- Authority
- JP
- Japan
- Prior art keywords
- sapacitabine
- metabolite
- treatment
- treatment cycle
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- LBGFKUUHOPIEMA-PEARBKPGSA-N sapacitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](C#N)[C@H](O)[C@@H](CO)O1 LBGFKUUHOPIEMA-PEARBKPGSA-N 0.000 claims 66
- 229950006896 sapacitabine Drugs 0.000 claims 65
- 239000002207 metabolite Substances 0.000 claims 62
- 239000003814 drug Substances 0.000 claims 38
- 229940124597 therapeutic agent Drugs 0.000 claims 36
- 230000001988 toxicity Effects 0.000 claims 16
- 231100000419 toxicity Toxicity 0.000 claims 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 230000002062 proliferating effect Effects 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 claims 3
- 229950000055 seliciclib Drugs 0.000 claims 3
- 108700020463 BRCA1 Proteins 0.000 claims 1
- 102000036365 BRCA1 Human genes 0.000 claims 1
- 101150072950 BRCA1 gene Proteins 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- DCYBPMFXJCWXNB-JWIUVKOKSA-N CNDAC Chemical group O=C1N=C(N)C=CN1[C@H]1[C@@H](C#N)[C@H](O)[C@@H](CO)O1 DCYBPMFXJCWXNB-JWIUVKOKSA-N 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010064571 Gene mutation Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 108010013296 Sericins Proteins 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 210000004602 germ cell Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 201000002665 lung leiomyosarcoma Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 230000003252 repetitive effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1208536.1A GB201208536D0 (en) | 2012-05-15 | 2012-05-15 | Dosing regimen |
| GB1208536.1 | 2012-05-15 | ||
| GB1304599.2 | 2013-03-14 | ||
| GB201304599A GB201304599D0 (en) | 2013-03-14 | 2013-03-14 | Dosing regimen |
| PCT/GB2013/051236 WO2013171473A1 (en) | 2012-05-15 | 2013-05-14 | Dosage regimen for sapacitabine and seliciclib |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015516459A JP2015516459A (ja) | 2015-06-11 |
| JP2015516459A5 true JP2015516459A5 (OSRAM) | 2016-07-14 |
| JP6286421B2 JP6286421B2 (ja) | 2018-02-28 |
Family
ID=48534436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015512121A Expired - Fee Related JP6286421B2 (ja) | 2012-05-15 | 2013-05-14 | サパシタビン及びセリシクリブの投与レジメン |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US9872874B2 (OSRAM) |
| EP (1) | EP2874631A1 (OSRAM) |
| JP (1) | JP6286421B2 (OSRAM) |
| WO (1) | WO2013171473A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201609758D0 (en) * | 2016-06-03 | 2016-07-20 | Cyclacel Ltd | Dosing Regimen |
| US10722515B2 (en) | 2016-09-30 | 2020-07-28 | Sri International | Dual CLK/CDK1 inhibitors for cancer treatment |
| US11524000B2 (en) | 2017-10-26 | 2022-12-13 | Emory University | Targeting Mcl-1 to enhance DNA replication stress sensitivity for cancer therapy |
| WO2021079129A1 (en) | 2019-10-24 | 2021-04-29 | Cyclacel Limited | Dosing regimen |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2559917B2 (ja) | 1990-06-15 | 1996-12-04 | 三共株式会社 | ピリミジンヌクレオシド誘導体 |
| FI105556B (fi) | 1991-09-30 | 2000-09-15 | Sankyo Co | Menetelmä lääkeaineina käyttökelpoisten pyrimidiiniukleosidijohdannaisten valmistamiseksi, joilla on kasvaimen vastaista vaikutusta |
| FR2741881B1 (fr) | 1995-12-01 | 1999-07-30 | Centre Nat Rech Scient | Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques |
| CA2231005A1 (en) | 1998-03-04 | 1999-09-04 | Libor Havlicek | Cyclin dependent kinase inhibitor |
| US6703395B2 (en) | 1998-03-04 | 2004-03-09 | Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic | Cyclin dependent kinase inhibitor |
| US6908906B2 (en) | 2001-02-09 | 2005-06-21 | Sankyo Company, Limited | Crystalline forms of pyrimidine nucleoside derivative |
| MXPA04009012A (es) | 2002-03-15 | 2004-12-07 | Cyclacel Ltd | Combinacion de inhibidor ofa cdk y 5 fu para el tratamiento de cancer. |
| JP2006508184A (ja) | 2002-11-06 | 2006-03-09 | サイクラセル・リミテッド | Ｃｄｋ阻害剤及びゲムシタビンを含む医薬組成物 |
| AU2003276467A1 (en) | 2002-11-06 | 2004-06-07 | Cyclacel Limited | Combination comprising docetaxel and a cdk inhibitor |
| MXPA05004920A (es) | 2002-11-06 | 2005-08-18 | Cyclacel Ltd | Combinacion que comprende un inhibidor cdk y cisplatin. |
| GB0225873D0 (en) | 2002-11-06 | 2002-12-11 | Cyclacel Ltd | Combination |
| GB0313511D0 (en) | 2003-06-11 | 2003-07-16 | Cyclacel Ltd | Combination |
| GB0315259D0 (en) | 2003-06-30 | 2003-08-06 | Cyclacel Ltd | Use |
| EP1680123A1 (en) | 2003-11-06 | 2006-07-19 | Cyclacel Limited | Use |
| GB0328180D0 (en) * | 2003-12-04 | 2004-01-07 | Cyclacel Ltd | Combination |
| US20080125404A1 (en) | 2004-08-27 | 2008-05-29 | Cyclacel Limited | Purine and Pyrimidine Cdk Inhitbitors and Their use for The Treatment of Autoimmune Diseases |
| GB0523041D0 (en) * | 2005-11-11 | 2005-12-21 | Cyclacel Ltd | Combination |
| GB0526419D0 (en) | 2005-12-23 | 2006-02-08 | Cyclacel Ltd | Formulation |
| GB0625283D0 (en) | 2006-12-19 | 2007-01-24 | Cyclacel Ltd | Combination |
| GB0706633D0 (en) | 2007-04-04 | 2007-05-16 | Cyclacel Ltd | Combination |
| JP5852309B2 (ja) * | 2007-04-25 | 2016-02-03 | サイクラセル リミテッド | 増殖性疾患を治療するためのサパシタビンの使用 |
| US8124593B2 (en) * | 2007-11-05 | 2012-02-28 | Cyclacel Limited | Methods of treatment using sapacitabine |
| GB0808357D0 (en) | 2008-05-08 | 2008-06-18 | Cyclacel Ltd | Process |
| US8530445B2 (en) | 2008-06-09 | 2013-09-10 | Cyclacel Limited | Combinations of sapacitabine or CNDAC with DNA methyltransferase inhibitors such as decitabine and procaine |
| WO2012140436A1 (en) | 2011-04-14 | 2012-10-18 | Cyclacel Limited | Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia |
-
2013
- 2013-05-14 US US14/401,357 patent/US9872874B2/en active Active
- 2013-05-14 JP JP2015512121A patent/JP6286421B2/ja not_active Expired - Fee Related
- 2013-05-14 EP EP13725424.9A patent/EP2874631A1/en not_active Withdrawn
- 2013-05-14 WO PCT/GB2013/051236 patent/WO2013171473A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3788047T3 (fi) | Fgft-estäjän kiinteitä muotoja ja menetelmiä niiden valmistamiseksi | |
| RU2018114447A (ru) | Введение дейтерированных усилителей cftr | |
| RU2010133489A (ru) | Применение ингибиторов гамма-секретазы для лечения рака | |
| HK1221646A1 (zh) | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 | |
| NZ586751A (en) | Use of CDDO methyl ester (methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate) for the treatment of renal diseases and for improving kigney function | |
| JP2018109022A5 (OSRAM) | ||
| JP2016518387A5 (OSRAM) | ||
| JP2015038135A5 (OSRAM) | ||
| JP2015521607A5 (OSRAM) | ||
| JP2015519329A5 (OSRAM) | ||
| JP2016185995A5 (OSRAM) | ||
| JP2013231087A5 (OSRAM) | ||
| NZ625592A (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| JP2013509411A5 (OSRAM) | ||
| RU2014141893A (ru) | Применение производной пиразола в лечении острых приступов хронической обструктивной болезни легких | |
| JP2020516646A5 (OSRAM) | ||
| RU2014150942A (ru) | Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона | |
| JP2015516459A5 (OSRAM) | ||
| WO2012142615A3 (en) | Auranofin and auranofin analogs useful to treat proliferative disease and disorders | |
| JP2021509395A5 (OSRAM) | ||
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| JP2018531273A5 (OSRAM) | ||
| JP2015508765A5 (OSRAM) | ||
| JP2017503846A5 (OSRAM) | ||
| RU2018146504A (ru) | Лечение внутрипеченочных холестатических заболеваний |